Dublin- and London-listed pharma services company has seen its order book grow 11% in first half from same period in 2022

Deal is Dublin-listed pharma company's first in the region in over 10 years

Company expects revenues from the contract to be recognised across 2022 and 2023

Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data

Executive chairman Cathal Friel said Hvivo expects to sign a number of similar contracts

Healthy volunteers are administered a pathogenic or virulent strain of virus

hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants

Contract with US biotechnology company concerns a respiratory syncytial virus

Irish clinical trials group will deliberately infect healthy young volunteers with virus

Guidelines will cover manufacture of agents for use in controlled infection studies

Contract with UK government could be worth up to £10m

Open Orphan’s hVivo unit will conduct world’s first human challenge trials of several vaccine candidates

Dublin listed company will carry out phase one trial at Hvivo facility

London subsidiary Hvivo will carry out testing at its lab with 48-hour turnaround

Issues with everything from drug trials to tech solutions, patient care are being tackled

As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world